- Time:
The robustness, flexibility, and adaptability of Chinese hamster ovary (CHO) cells have made them the “go-to” system for the stable production of a plethora of therapeutic proteins. These protein products include monoclonal antibodies and more complex architectures, such as multi-specifics or fusion polypeptides commonly used in drug development. Biopharmaceutical companies are always looking at increasing the robustness of their manufacturing processes to achieve adequate product yields while controlling their quality.
This drive has resulted in organizations using the same expression systems in their discovery activities that they will utilize later during cell line development (CLD) and clinical manufacturing. This approach has several benefits: on the one hand, it generates early knowledge of how different products will behave and enables the implementation of corrective actions if productivity or quality issues are detected. Also, it guarantees consistency in product quality across different stages of development, which opens the door to bringing forward development activities that would otherwise be in the critical path for development. Horizon Discovery’s CHOSOURCE™ GS knockout cell line facilitates this by providing optimal performance across the entire discovery-development continuum, as this webinar will demonstrate.
In this GEN Webinar, we will hear from the experiences of two scientists working in different departments at Jounce Therapeutics that have integrated the CHOSOURCE platform to build efficiencies across their drug development workflow. Using their own experiences and case studies, out presenters will highlight the benefits of transient and stable transfections of CHO cell lines for various production purposes.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Michael Cullivan
Associate Scientist
Jounce Therapeutics
Andrea Gough
Product Manager, Bioproduction
Horizon Discovery
